Papaluca T et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2021;73(9):e3288–e3295.

CAS  PubMed  Article  Google Scholar 

Mate-Cano I, et al. Epidemiological trend of hepatitis C-related liver events in Spain (2000–2015): a nationwide population-based study. Eur J Intern Med. 2020;75:84–92

PubMed  Article  Google Scholar 

Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin N Am. 2015;44(4):717–734

Article  Google Scholar 

Planas R, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40(5):823–830

PubMed  Article  Google Scholar 

Nabatchikova EA, et al. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: a long-term single-center experience. Clin Res Hepatol Gastroenterol. 2021;45(6): 101714

PubMed  Article  Google Scholar 

Verna EC, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73(3):540–548

CAS  PubMed  Article  Google Scholar 

Pereira Guedes T, et al. Long-term follow-up of advanced liver disease after sustained virological response to treatment of hepatitis C with direct-acting antivirals: outcomes from a real-world Portuguese cohort. GE Port J Gastroenterol. 2020;27(3):149–159

PubMed  Article  Google Scholar 

Chhatwal J, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65(3):777–788

PubMed  Article  Google Scholar 

Lawitz E, et al. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep. 2020;3(2): e145

PubMed  PubMed Central  Article  Google Scholar 

Martini S, et al. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: a national real-life experience. Liver Int. 2018;38(4):733–741

CAS  PubMed  Article  Google Scholar 

Bittermann T, Reddy KR. In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent. Clin Gastroenterol Hepatol. 2021;19(11):2389–2397

PubMed  Article  Google Scholar 

Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series(☆). J Hepatol. 2020;73(5):1170–1218

Article  Google Scholar 

AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA; 2022

Ferrarese A, et al. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: a single-center study. World J Gastroenterol. 2018;24(38):4403–4411

PubMed  PubMed Central  Article  Google Scholar 

Saez-Gonzalez E, et al. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int. 2018;38(6):1022–1027

CAS  PubMed  Article  Google Scholar 

Dellay B, et al. Impact of sofosbuvir-based therapy on liver transplant candidates with hepatitis C virus infection. Pharmacother J Hum Pharmacol Drug Therapy. 2019;39(4):424–432

CAS  Article  Google Scholar 

Al-Judaibi B, et al. Sofosbuvir-based therapy in the pre-liver transplant setting: the Canadian national experience. Ann Hepatol. 2018;17(3):437–443

CAS  PubMed  Article  Google Scholar 

Rao H, et al. Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. JHEP Rep. 2020;2(4): 100136

PubMed  PubMed Central  Article  Google Scholar 

Krassenburg LAP et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74(5):1053–1063

PubMed  Article  Google Scholar 

Beinhardt S, et al. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int. 2018;38(7):1188–1197

CAS  PubMed  Article  Google Scholar 

Huang AC, et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018;68(2):449–461

CAS  PubMed  Article  Google Scholar 

Zanetto A, et al. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl. 2017;23(9):1103–1112

PubMed  Article  Google Scholar 

Cheung MCM, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65(4):741–747

CAS  PubMed  Article  Google Scholar 

Yoshida EM, et al. Persistence of virologic response after liver transplant in hepatitis C patients treated with ledipasvir / sofosbuvir plus ribavirin pretransplant. Ann Hepatol. 2017;16(3):375–381

CAS  PubMed  Article  Google Scholar 

Herzer K, et al. Real-world experience with daclatasvir plus sofosbuvir +/- ribavirin for post-liver transplant HCV recurrence and severe liver disease. Transpl Int. 2017;30(3):243–255

CAS  PubMed  Article  Google Scholar 

Fontana RJ, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22(4):446–458

PubMed  Article  Google Scholar 

Forns X, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485–1494

CAS  PubMed  Article  Google Scholar 

Pellicelli AM, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46(10):923–927

CAS  PubMed  Article  Google Scholar 

Punzalan CS, et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015;29(12):1105–1111

CAS  PubMed  Article  Google Scholar 

Sandmann L, et al. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. Eur J Gastroenterol Hepatol. 2019;31(8):1049–1056

CAS  PubMed  Article  Google Scholar 

Sanchez Antolin G, et al. Efficacy and safety of therapy with simeprevir and sofosbuvir in liver transplant recipients infected by hepatitis C virus genotype 4: cohort spanish society of liver transplantation cohort. Transpl Proc. 2016;48(9):3013–3016

CAS  Article  Google Scholar 

Morisco F, et al. Optimization of direct anti-viral agent treatment schedule: focus on HCV genotype 3. United Eur Gastroenterol J. 2018;6(2):225–237

CAS  Article  Google Scholar 

Garcia-Pajares F, et al. Efficacy of direct-acting antivirals to improve clinical condition, fibrosis, and liver function in liver transplant recipients infected by hepatitis C. Transpl Proc. 2019;51(1):74–76

CAS  Article  Google Scholar 

Abaalkhail F, et al. Treatment of patients with hepatitis C virus infection with ledipasvir-sofosbuvir in the liver transplant setting. Transplantation. 2017;101(11):2739–2745

CAS  PubMed  Article  Google Scholar 

Kwo P, et al. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. Hepatol Commun. 2018;2(4):354–363

CAS  PubMed  PubMed Central  Article  Google Scholar 

Manns M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–697

CAS  PubMed  Article  Google Scholar 

Fernández Carrillo C, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology. 2017;65(6):1810–1822

PubMed  Article  CAS  Google Scholar 

Hill LA, et al. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2018;30(11):1378–1383

CAS  PubMed  Article  Google Scholar 

Kandemir MH, et al. Efficacy of posttransplant ledipasvir-sofosbuvir in the treatment of patients who have undergone chronic hepatitis C-related liver transplant. Exp Clin Transplant. 2020. https://doi.org/10.6002/ect.2019.0183

Article  PubMed  Google Scholar 

Lionetti R, et al. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: a prospective study. Clin Transplant. 2018;32(2):02

Article  CAS  Google Scholar 

Poordad F, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505

CAS  PubMed  Article  Google Scholar